Current prognostic and predictive biomarkers for CRC include mutations in RAS family (KRAS, NRAS, HRAS) and BRAF (V600E) as well as microsatellite instability (MSI) status [36,37,38,39]. This evidence concerns the gene KRAS and colorectal carcinoma.